{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:21Z","timestamp":1791474681258,"version":"4.3.4"},"reference-count":52,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Follicular lymphoma (FL) accounts for \u223c20% of all new lymphoma cases. Increases in cytological grade are a feature of the clinical progression of this malignancy, and eventual histologic transformation (HT) to the aggressive diffuse large B-cell lymphoma (DLBCL) occurs in up to 15% of patients. Clinical or genetic features to predict the risk and timing of HT have not been described comprehensively. In this study, we analyzed whole-genome sequencing data from 423 patients to compare the protein coding and noncoding mutation landscapes of untransformed FL, transformed FL, and de novo DLBCL. This revealed 2 genetically distinct subgroups of FL, which we have named DLBCL-like (dFL) and constrained FL (cFL). Each subgroup has distinguishing mutational patterns, aberrant somatic hypermutation rates, and biological and clinical characteristics. We implemented a machine learning\u2013derived classification approach to stratify patients with FL into cFL and dFL subgroups based on their genomic features. Using separate validation cohorts, we demonstrate that cFL status, whether assigned with this full classifier or a single-gene approximation, is associated with a reduced rate of HT. This implies distinct biological features of cFL that constrain its evolution, and we highlight the potential for this classification to predict HT from genetic features present at diagnosis.<\/jats:p>","DOI":"10.1182\/blood.2022018719","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:39:23Z","timestamp":1682109563000},"page":"561-573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns"],"prefix":"10.1182","volume":"142","author":[{"given":"Kostiantyn","family":"Dreval","sequence":"first","affiliation":[{"name":"1Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"},{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Cruz","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Shaalan","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ben-Neriah","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill","family":"Boyle","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-2798","authenticated-orcid":false,"given":"Brett","family":"Collinge","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-4873","authenticated-orcid":false,"given":"Krysta M.","family":"Coyle","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Duns","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-9391","authenticated-orcid":false,"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4621-1589","authenticated-orcid":false,"given":"Bruno M.","family":"Grande","sequence":"additional","affiliation":[{"name":"4Sage Bionetworks, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Meissner","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-3552","authenticated-orcid":false,"given":"Prasath","family":"Pararajalingam","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Rushton","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-6517","authenticated-orcid":false,"given":"Jasper","family":"Wong","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2742","authenticated-orcid":false,"given":"Andrew J.","family":"Mungall","sequence":"additional","affiliation":[{"name":"1Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Marra","sequence":"additional","affiliation":[{"name":"1Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7800","authenticated-orcid":false,"given":"Ryan D.","family":"Morin","sequence":"additional","affiliation":[{"name":"1Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"},{"name":"2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2023081015251918700_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clml.2014.07.015","article-title":"A\u00a0Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board","volume":"15","author":"Kuruvilla","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"2023081015251918700_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3747\/co.23.3405","article-title":"Emerging therapies for the treatment of relapsed or refractory follicular lymphoma","volume":"23","author":"MacDonald","year":"2016","journal-title":"Curr Oncol"},{"key":"2023081015251918700_bib3","author":"Swerdlow","year":"2008"},{"issue":"1","key":"2023081015251918700_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2023081015251918700_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10552-019-01155-5","article-title":"Global patterns and trends in the incidence of non-Hodgkin lymphoma","volume":"30","author":"Miranda-Filho","year":"2019","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2023081015251918700_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2023081015251918700_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2023081015251918700_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"2023081015251918700_bib9","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"7360","key":"2023081015251918700_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2023081015251918700_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol"},{"issue":"22","key":"2023081015251918700_bib12","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1182\/bloodadvances.2020002944","article-title":"Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease","volume":"4","author":"Nann","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023081015251918700_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","article-title":"Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations","volume":"128","author":"Louissaint","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2023081015251918700_bib14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-05-500264","article-title":"Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023081015251918700_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"suppl 1","key":"2023081015251918700_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2222","article-title":"XIV. The pathology of transformation of indolent B cell lymphomas","volume":"33","author":"Gascoyne","year":"2015","journal-title":"Hematol Oncol"},{"issue":"1","key":"2023081015251918700_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed follicular lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"2023081015251918700_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.hoc.2020.02.010","article-title":"The biological basis of histologic transformation","volume":"34","author":"Kumar","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"S2","key":"2023081015251918700_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hon.40_2879","article-title":"Molecular subclusters of follicular lymphoma: a report from the UK\u2019s Haematological Malignancy Research Network","volume":"39","author":"Crouch","year":"2021","journal-title":"Hematological Oncology"},{"issue":"3","key":"2023081015251918700_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"issue":"8","key":"2023081015251918700_bib21","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"13","key":"2023081015251918700_bib22","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","article-title":"Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes","volume":"99","author":"Lossos","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2023081015251918700_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2023081015251918700_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"2023081015251918700_bib25","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.leu.2404696","article-title":"Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma","volume":"21","author":"Fitzgibbon","year":"2007","journal-title":"Leukemia"},{"issue":"6769","key":"2023081015251918700_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"3","key":"2023081015251918700_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023081015251918700_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2023081015251918700_bib29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023081015251918700_bib30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2023081015251918700_bib31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.2022016534","article-title":"Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma","volume":"141","author":"Thomas","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2023081015251918700_bib32","doi-asserted-by":"crossref","first-page":"e153283","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"21","key":"2023081015251918700_bib33","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1182\/bloodadvances.2021005284","article-title":"Molecular subclusters of follicular lymphoma: a report from the UK\u2019s Haematological Malignancy Research Network","volume":"6","author":"Crouch","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023081015251918700_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023081015251918700_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"issue":"18","key":"2023081015251918700_bib36","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/bloodadvances.2020002546","article-title":"Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models","volume":"4","author":"Alig","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2023081015251918700_bib37","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023081015251918700_bib38","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"2023081015251918700_bib39","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023081015251918700_bib40","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023081015251918700_bib41","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun"},{"issue":"18","key":"2023081015251918700_bib42","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2023081015251918700_bib43","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41375-021-01251-z","article-title":"Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas","volume":"35","author":"H\u00fcbschmann","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"2023081015251918700_bib44","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.2022016095","article-title":"Minimal information for reporting a genomics experiment","volume":"140","author":"Dreval","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2023081015251918700_bib45","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","article-title":"High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology","volume":"2","author":"Chong","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2023081015251918700_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2023081015251918700_bib47","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood-2018-06-855502","article-title":"miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels","volume":"132","author":"Musilova","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2023081015251918700_bib48","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice","volume":"129","author":"Garc\u00eda-Ram\u00edrez","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023081015251918700_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s42003-020-01119-5","article-title":"Mutational signature SBS8 predominantly arises due to late replication errors in cancer","volume":"3","author":"Singh","year":"2020","journal-title":"Commun Biol"},{"issue":"10","key":"2023081015251918700_bib50","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2023081015251918700_bib51","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/onc.2009.377","article-title":"c-Myc overexpression promotes a germinal center-like program in Burkitt\u2019s lymphoma","volume":"29","author":"Scheller","year":"2010","journal-title":"Oncogene"},{"issue":"3","key":"2023081015251918700_bib52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/6\/561\/2070108\/blood_bld-2022-018719-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/6\/561\/2070108\/blood_bld-2022-018719-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:27:56Z","timestamp":1691681276000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/6\/561\/495422\/Genetic-subdivisions-of-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018719","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}